Humacyte, Inc. (HUMA)
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Humacyte, Inc.
NASDAQ:HUMAHealthcare · Biotechnology
-12.47%$0.4112
AH$0.4289+4.30%vs close
Mkt Cap$114.23M
Float275.6M
O/S277.8M
Vol
$ Vol
RVOL
Inst Own26.5%
SI11.0%
Earnings
Dilution
Financials Summary
Revenue$2.04M
Net Income-$40.83M
Total Assets$116.37M
Free Cash Flow-$105.93M
Debt & Equity
Debt 95%
Equity 5%
Total Debt$64.85M
Total Equity$3.11M
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in HUMA's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$116.37M
Liabilities$113.26M
Accounts Receivable$441K
Accounts Payable$5.4M
Inventory$13.59M
PP&E (Net)$47.69M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Revenue | $2.04M | $0 | $0 | $1.56M | $1.26M | $1.49M | $6.19M |
| YoY Growth | - | - | - | 23.9% | -15.3% | -75.9% | - |
| Cost of Revenue | $17.05M | $7.19M | $76.55M | $8.26M | $61.34M | $54.08M | $75.6M |
| Gross Profit | -$15.01M | -$7.19M | -$76.55M | -$6.69M | -$60.08M | -$52.59M | -$69.42M |
| Gross Margin | -736.5% | - | - | -427.5% | -4756.8% | -3527.0% | -1122.0% |
| Research and Development | $69.3M | $88.6M | $76.55M | $63.26M | $61.34M | $54.08M | $75.6M |
| Selling, General, and Administrative | $31.17M | $25.8M | $20.39M | $22.88M | $21.13M | $12.01M | $16.27M |
| Other | -$8.04M | -$7.19M | -$73.44M | -$8.26M | -$61.34M | -$54.08M | -$75.6M |
| Total Operating Expenses | $92.43M | $107.21M | $23.5M | $77.89M | $21.13M | $12.01M | $16.27M |
| Operating Income (EBIT) | -$107.44M | -$114.4M | -$100.05M | -$84.58M | -$81.21M | -$64.6M | -$85.69M |
| Operating Margin | -5271.7% | - | - | -5404.3% | -6429.8% | -4332.7% | -1385.0% |
| Interest Expense | $11.25M | $9.28M | $6.6M | $6.2M | $4.35M | $2.2M | $2.3M |
| Interest Income | $2.59M | $4.1M | $5.47M | $2.63M | $16K | $278K | $269K |
| Other Income (Expense) | $66.6M | -$34.3M | -$10.73M | $72.61M | $54.73M | -$1.92M | $269K |
| Income Before Tax (EBT) | -$40.83M | -$148.7M | -$110.78M | -$11.96M | -$26.48M | -$66.52M | -$85.42M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$40.83M | -$148.7M | -$110.78M | -$11.96M | -$26.48M | -$66.52M | -$85.42M |
| Net Income Margin | -2003.6% | - | - | -764.5% | -2096.4% | -4461.7% | -1380.7% |
| Supplementary Data | |||||||
| EPS | -0.26 | -1.26 | -1.07 | -0.12 | -0.66 | -5.52 | -4.25 |
| Diluted EPS | -0.26 | -1.26 | -1.07 | -0.12 | -0.66 | -5.52 | -4.25 |
| Weighted Average OS | 158.16M | 118.48M | 103.42M | 103.05M | 39.97M | 12.45M | 103.00M |
| EBITDA | -$22.24M | -$132.23M | -$96.46M | $2.44M | -$13.89M | -$56.25M | -$78.94M |
| EBITDA Margin | -1091.2% | - | - | 156.2% | -1099.6% | -3772.6% | -1275.9% |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Assets | |||||||
| Current Assets | |||||||
| Cash and Cash Equivalents | $50.5M | $44.94M | $80.45M | $149.77M | $217.5M | $39.93M | $93.71M |
| Short-Term Investments | $0 | $0 | $0 | $2.11M | $8M | $0 | $0 |
| Cash and Short-Term Investments | $50.5M | $44.94M | $80.45M | $151.88M | $225.5M | $39.93M | $93.71M |
| Accounts Receivable | $441K | $0 | $0 | $31K | $176K | $113K | $601K |
| Inventory | $13.59M | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $3.27M | $2.92M | $2.83M | $2.3M | $0 | $0 | $0 |
| Total Current Assets | $67.8M | $47.86M | $83.28M | $154.21M | $229.34M | $41.45M | $94.95M |
| Long-Term Assets | |||||||
| Property, Plant & Equipment Net | $47.69M | $38.55M | $44.1M | $50.09M | $57.19M | $65.24M | $73.74M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $209K | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $672K | $51.46M | $841K | $0 | $0 | $0 | $0 |
| Total Long-Term Assets | $48.57M | $90.01M | $44.95M | $50.09M | $57.19M | $65.24M | $73.74M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $116.37M | $137.87M | $128.22M | $204.3M | $286.53M | $106.69M | $168.69M |
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts Payable | $5.4M | $4.49M | $6.49M | $1.59M | $2.09M | $2.27M | $3.27M |
| Short-Term Debt | $0 | $0 | $0 | $8.57M | $0 | $2.45M | $1.5M |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $173K | $145K | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $6.63M | $7.37M | $5.29M | $4.23M | $4.12M | $1.15M | -$1.5M |
| Total Current Liabilities | $18.37M | $19.95M | $18.44M | $19.58M | $11.05M | $11.23M | $10.84M |
| Long-Term Liabilities | |||||||
| Long-Term Debt | $35.44M | $0 | $38.6M | $20.34M | $27.36M | $822K | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $32.47M | $156.97M | $41.34M | $28.61M | $104.16M | $144K | $0 |
| Total Long-Term Liabilities | $94.89M | $170.59M | $96.23M | $67.79M | $153.31M | $24.78M | $25.65M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $113.26M | $190.54M | $114.68M | $87.37M | $164.36M | $36.02M | $36.49M |
| Stockholders' Equity | |||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $420.99M | $420.99M |
| Common Stock | $20K | $13K | $10K | $10K | $10K | $1K | $21K |
| Retained Earnings | -$726.85M | -$686.01M | -$537.31M | -$426.54M | -$414.57M | -$388.1M | -$321.57M |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $729.94M | $633.33M | $550.85M | $543.46M | $536.74M | $458.77M | $453.75M |
| Total Equity | $3.11M | -$52.67M | $13.55M | $116.93M | $122.17M | $70.67M | $132.2M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $116.37M | $137.87M | $128.22M | $204.3M | $286.53M | $106.69M | $168.69M |
| Supplementary Data | |||||||
| Total Debt | $64.85M | $16.54M | $57.45M | $50.07M | $51.18M | $28.86M | $28.72M |
| Net Debt | $14.35M | -$28.4M | -$23M | -$99.71M | -$166.32M | -$11.07M | -$65M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Operating Activities | |||||||
| Net Income | -$40.83M | -$148.7M | -$110.78M | -$11.96M | -$26.48M | -$66.52M | -$85.42M |
| Depreciation & Amortization | $7.34M | $7.19M | $7.72M | $8.21M | $8.24M | $8.35M | $6.75M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | -$4.27M |
| Stock-Based Compensation | $9.75M | $6.14M | $6.83M | $6.18M | $10.15M | $0 | $4.46M |
| Changes in Working Capital: | |||||||
| Accounts Receivable | -$261K | $0 | $31K | $145K | -$63K | $488K | -$185K |
| Inventory | -$21.83M | $0 | $0 | $0 | $0 | $0 | -$2.43M |
| Accounts Payable | $973K | -$1.96M | $4.81M | -$509K | -$197K | -$889K | $2.43M |
| Other Working Capital | -$2.28M | $2.27M | $1.73M | $1.39M | -$297K | -$1.97M | $638K |
| Total Working Capital Change | -$23.39M | $311K | $6.57M | $1.03M | -$557K | -$2.37M | $453K |
| Other Non-Cash Items | -$57.91M | $36.94M | $16.35M | -$74.59M | -$72.54M | $4.97M | $6.25M |
| Net Cash from Operating | -$105.04M | -$98.12M | -$73.31M | -$71.13M | -$81.19M | -$55.57M | -$71.79M |
| Investing Activities | |||||||
| Capital Expenditures | -$884K | -$1.57M | -$2.28M | -$1.05M | -$220K | -$318K | -$8.13M |
| Acquisitions | $0 | $0 | $0 | $0 | $0 | $50K | $0 |
| Purchases of Investments | $0 | $0 | $0 | -$10.11M | -$8M | $0 | $0 |
| Sales of Investments | $0 | $0 | $2.11M | $16M | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$884K | -$1.57M | -$173K | $4.84M | -$8.22M | -$268K | -$8.13M |
| Financing Activities | |||||||
| Debt Repaid | -$36.38M | $2.58M | -$5.7M | $1.98M | -$27.93M | -$1.75M | $1.29M |
| Common Stock Issuance | $113.44M | $45.93M | $566K | $535K | $598K | $301K | $0 |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$88.34M | $27.71M | -$1.76M | $0 | $239.05M | $0 | $1.22M |
| Net Cash from Financing | $61.49M | $114.18M | $4.51M | -$1.45M | $266.98M | $2.05M | -$74K |
| Forex Effect | $0 | $0 | -$209K | $0 | $0 | $93.71M | $173.7M |
| Net Change in Cash | -$44.44M | $14.49M | -$69.18M | -$67.73M | $177.57M | $39.93M | -$79.99M |
| Supplementary Data | |||||||
| Operating Cash Flow | -$105.04M | -$98.12M | -$73.31M | -$71.13M | -$81.19M | -$55.57M | -$71.79M |
| Capital Expenditure | -$884K | -$1.57M | -$2.28M | -$1.05M | -$220K | -$318K | -$8.13M |
| Free Cash Flow | -$105.93M | -$99.69M | -$75.58M | -$72.18M | -$81.41M | -$55.89M | -$79.91M |
| Cash at Beginning | $95.29M | $80.8M | $149.77M | $217.5M | $39.93M | $0 | $173.7M |
| Cash at End | $50.85M | $95.29M | $80.59M | $149.77M | $217.5M | $39.93M | $93.71M |